Compounds > 20-hydroperoxycholesterol
Page last updated: 2024-12-10

20-hydroperoxycholesterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

20-hydroperoxycholesterol: RN given refers to (3 beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3082219
SCHEMBL ID7145979
MeSH IDM0114678

Synonyms (17)

Synonym
cholest-5-en-3-ol, 20-hydroperoxy-, (3beta)-
491k3lyv0f ,
23653-01-2
cholesterol-20-hydroperoxide
unii-491k3lyv0f
20-hydroperoxycholesterol
SCHEMBL7145979
cholest-5-en-3.beta.-ol, 20-hydroperoxy-, (20s)-
20.alpha.-hydroperoxycholesterol
3.beta.-hydroxycholest-5-ene 20.alpha.-hydroperoxide
cholesterol 20.alpha.-hydroperoxide
cholest-5-en-3-ol, 20-hydroperoxy-, (3.beta.)-
(3.beta.)-20-hydroperoxycholest-5-en-3-ol
20-hydroperoxycholest-5-en-3beta-ol
Q27896160
20-hydroperoxycholest-5-en-3-ol
DTXSID50946469
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.46 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbon monoxide
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.		1.9710carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
22-hydroxycholesterol
[no description available]		2.0310cholanoid
cholesterol hydroperoxide
cholesterol hydroperoxide: RN given refers to (3beta,5beta)-isomer		1.9710
desmosterol
Desmosterol: An intermediate in the synthesis of cholesterol.. desmosterol : A cholestanoid that is cholesta-5,24-diene substituted by a beta-hydroxy group at position 3. It is an intermediate metabolite obtained during the synthesis of cholesterol.		2.03103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C27-steroid;
cholestanoid		human metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		01.9710